Journal of Aging Science

Prevention of Osteoporosis in Older Persons

Roger Wilson^* Department of Geriatrics, University of Leicester, Leicester, United Kingdom
^*Correspondence: Roger Wilson, Department of Geriatrics, University of Leicester, Leicester, United Kingdom, Email:

Received: 02-Jan-2023, Manuscript No. JASC-23-19650; Editor assigned: 05-Jan-2023, Pre QC No. JASC-23-19650 (PQ); Reviewed: 20-Jan-2023, QC No. JASC-23-19650; Revised: 26-Jan-2023, Manuscript No. JASC-23-19650 (R); Published: 03-Feb-2023, DOI: 10.35248/2329-8847.23.11.297

Description

Bone is made up of living tissue that is constantly changing. Humans rely on the minerals calcium and phosphate throughout their lives to keep our bones strong and healthy. It is often called a “silent” disease. The disease can progress undetected for years before fractures occur. It can lead to painful, debilitating fractures called fragility fractures. These fractures are associated with increased medical costs, disability, decreased quality of life, and increased mortality. Because the incidence of osteoporotic fractures increases with age, measures to diagnose and prevent osteoporosis and its complications are of great public health importance. Bone Mineral Density (BMD) is a valuable tool for identifying patients at risk of fracture, making therapeutic decisions, and monitoring treatment. Several other modifiable and non-modifiable risk factors for osteoporosis have also been identified.

Osteoporosis affects approximately 54 million people in the United States. The disease affects both men and women, but women are four times more likely to develop it than men. The risk of osteoporosis increases with age, and many women develop it after menopause. The hormone estrogen helps build and rebuild bones. Estrogen levels in women decline after menopause, accelerating bone loss. This is why osteoporosis is most common in older women. Hip fractures are the most costly and best documented complication of osteoporosis.

The Dachverband Osteologie (DVO) is a three-national umbrella organization of 21 medical-scientific societies currently dealing with bone diseases. Over the last 20 years, DVO has established a high quality concept for the care of patients with bone disease. Osteoporosis, a widespread disease affecting 6-7 million people in Germany alone, certainly plays a central role in the DVO activity, such as Paget's disease, bone metastases, primary benign and malignant bone Other bone diseases such as tumors and rare bone diseases were also covered. In March 2003, the German osteological umbrella organization DVO published guidelines for the diagnosis and treatment of osteoporosis. To prevent fractures in postmenopausal and senile osteoporotic women, these guidelines recommend her three treatment options as first-line treatment which involves three drugs such as risedronate, alendronate, raloxifene. There is currently no evidence that raloxifene reduces hip fractures. Therefore, only risedronate and alendronate are recommended for hip fracture prevention. Information on the cost-effectiveness of osteoporosis prevention and treatment can help decision-makers allocate resources more efficiently. Management of potentially modifiable risk factors, along with exercise and calcium and vitamin D supplementation, are important adjuncts to the pharmacological treatment of osteoporosis. Improving home security can reduce the risk of falls. Hip protectors have proven effective in nursing homes.

Calcium is a mineral that makes bones strong. It can be obtained from the daily foods, such as milk and dairy products, dark green leafy vegetables such as kale and collards, and supplements. Women over the age of 50 need 1,200 mg of calcium daily. For men, from age 51 until she is 70 she needs 1,000 mg per day, after which she needs 1,200 mg per day. Vitamin D helps the body absorb calcium. It is also produced endogenously when Ultraviolet (UV) lights from the sun hits the skin and activates vitamin D synthesis.